This study is a single-arm, open-label, non-randomized clinical trial aimed at evaluating the safety, tolerability and preliminary efficacy of HY001N cell injection in the treatment of patients with relapsed/refractory Neurological Autoimmune Diseases.
Patients who are willing to sign the informed consent form;
Aged 18-75 years, male or female;
aquaporin 4 (AQP4) -IgG positive
At least one immunosuppressant has been used for more than one year and the symptoms have not been well controlled;
Current medical conditions or neurological disorders that may affect the effectiveness assessment, such as dementia, schizophrenia, bipolar disorder, major depressive disorder, history of multiple traumatic brain injury, current alcohol/drug abuse or dependence, or alcohol/drug dependence within the past two years.
Pregnancy or breastfeeding;
Have received organ or hematopoietic stem cell transplantation in the past;
There has been a history of new thrombosis or organ infarction within the past six months;
Juventas Cell Therapy Ltd.
Lead sponsor
Beijing Tiantan Hospital
Collaborator